Net sales for the three months ended March 31, 2009 totaled $72,856,000 an increase of $757,000 or 1%, over the $72,099,000 in net sales reported for the three months ended March 31, 2008. Net income for the three months ended March 31, 2009 was $1,772,000 or $.11 per basic and diluted share versus $2,797,000 or $.18 per basic share ($.17 per diluted share), reported for the comparable three months of fiscal 2008.

Medical Action reported a 44% sequential increase in gross profit between the third and fourth quarters of fiscal 2009, with gross margin rising from 14.0% to 19.9% between the two periods.

"These and other improving business trends demonstrate that Medical Action has made significant progress in managing its near-term business challenges and, with a continued focus on improvement, is poised to take advantage of growth opportunities in fiscal 2010," Meringolo said. "We have managed through a volatile period of fluctuating commodity prices as well as the pricing of foreign sourced products. We have hedged against near term resin price volatility by taking inventory positions in our high volume resins. We have begun to benefit from better pricing of Chinese-made products and we continue to monitor both exchange rates and commodity prices. We remain focused on further increasing the efficiency of our Gallaway, Tennessee manufacturing facility after making significant equipment upgrades during the year and appointing a new plant general manager in April.

Net sales for the twelve months ended March 31, 2009 reached a record $296,070,000 an increase of $5,542,000 or 1.9%, over the $290,528,000 in net sales reported for the twelve months ended March 31, 2008. This was Medical Action's 14th consecutive year of record revenue. Net income for the period was $4,955,000 or $.31 per basic and diluted share, versus $13,225,000 or $.83 per basic share ($.81 per diluted share), reported for the comparable twelve months in fiscal 2008.

"While we are pleased with our record revenue," Meringolo said, "there's no question we have come off a challenging year that adversely affected our profitability. Our three primary business challenges -- higher resin costs due to record oil prices, increased costs for Chinese-made products and inefficiencies in the Tennessee plant -- cost a combined $16,194,000 in fiscal 2009."

Meringolo further noted, "Our fiscal 2009 initiatives included the appointments of veteran, senior-level executives directing sales, sales operations, and training & development." The realignment of sales territories and the reorganization and re-training of sales teams should drive enhanced productivity and accountability.

The Company also announced that the US Food and Drug Administration, FDA, completed a re-inspection of Medical Action's Arden NC facility and it was found to be in compliance with the FDA Quality Systems Regulations with no adverse findings noted.